# Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.

> **NCT07654530** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 107 (actual)

## Conditions studied

- Biliary Tract Cancers (BTC)

## Interventions

- **DRUG:** Sintilimab + Ipilimumab (N01) + AG
- **DRUG:** Sintilimab Combined with Albumin-bound Paclitaxel and Gemcitabine (AG)

## Key facts

- **NCT ID:** NCT07654530
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654530, "Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*